Elite Pharmaceuticals Revenue
Pharmaceutical Manufacturing • 
United States • 51-100 Employees
Elite Pharmaceuticals revenue & valuation
| Annual revenue | $105,500,000 |
| Revenue per employee | $1,598,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $337,500,000 |
| Total funding | $500,000 |
Key Contacts at Elite Pharmaceuticals
Matthew Giles
Director, Qc And Ar&D
Khaled Youssef Mayouf
Chief Executive Officer
Sharen Sharp
Director Of Regulatory Affairs
Peter Kinkel
Director Qc
Company overview
| Headquarters | United States |
| Phone number | +12017502646 |
| Website | |
| NAICS | 3254 |
| SIC | 283 |
| Keywords | Contract Manufacturing, Generic Drugs, Specialty Pharmaceuticals, Controlled Release Drug Products, Extended Release Drug Products |
| Founded | 1996 |
| Employees | 51-100 |
| Socials |
Elite Pharmaceuticals Email Formats
Elite Pharmaceuticals uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@elitepharma.com), used 65% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@elitepharma.com | 65% |
{first initial}{last name} | jdoe@elitepharma.com | 35% |
About Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals (“ECR”), a wholly owned subsidiary of Hi-Tech Pharmacal (“Hi-Tech”). Elite’s lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Elite Pharmaceuticals has 36 employees across 10 departments.
Departments
Number of employees
Elite Pharmaceuticals Tech Stack
Discover the technologies and tools that power Elite Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.
WordPress plugins
JavaScript libraries
Maps
JavaScript libraries
CDN
Advertising
JavaScript libraries
Miscellaneous
Security
Programming languages
Blogs
Widgets
Spain
Canada
South Africa
Frequently asked questions
4.8
40,000 users
